To investigate the safety and performance of the Eyedeal® PX65AS1 intraocular lens (IOL)~To evaluate the safety profile with regards to best-corrected visual acuity, and adverse events~To evaluate the performance with regards of best corrected distance VA after the device implantation~The Eyedeal® IOL (model PX65AS1) is a clear foldable single-piece ultra-violet absorbing posterior chamber monofocal IOL. It is an optical implant for the replacement of the human crystalline lens in the visual correction of aphakia in adult patients after cataract surgery. The Eyedeal® IOL is made of a high refractive index soft hydrophobic crosslinked polyisobutylene material. It is composed of an equi-convex all-optical surface and double C-loop haptics. The front and rear optical surfaces are equi-convex aspheric surfaces with no spherical aberration. The haptics ensure that the lens centration and fixation. IOL powers vary from +0.5D to 30D with 0.5D increment and from +30D to +34D with 1.0D increment. The optical diameter is 6.5 mm and the overall length is 13.0 mm.
A cataract is the clouding of the natural lens in the eye and is very common as when getting older. A cloudy lens makes it difficult to see. A cataract is treated by removing the cloudy lens and replacing it with an intraocular lens (known as an IOL). The goal of this clinical trial is to determine if the Eyedeal® IOL can be safely implanted in a subject's eye and if it can replace efficiently the natural lens.~Subjects will be asked to attend a total of seven visits for this study for a period of 12 months after surgery.